The aminoglycosides

Mayo Clinic Proceedings

Volumn 74, Issue 5, 1999, Pages 519-528

  Edson, Randall S ^a   Terrell, Christine L ^a  

^a MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; GENTAMICIN; NETILMICIN; STREPTOMYCIN; TOBRAMYCIN;

CONFERENCE PAPER; DRUG CHOICE; DRUG COST; DRUG FEVER; DRUG MECHANISM; ENTEROCOCCUS; GRAM NEGATIVE INFECTION; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIOSIS; NEPHROTOXICITY; NEUROTOXICITY; NOCARDIA; OTOTOXICITY; PSEUDOMONAS AERUGINOSA; RASH; STREPTOCOCCUS INFECTION; TUBERCULOSIS; TULAREMIA; URINARY TRACT INFECTION;

EID: 0032891012     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/74.5.519     Document Type: Conference Paper

References (92)

1. Moellering RC Jr, Wennersten C, Weinberg AN. Studies on antibiotic synergism against enterococci. I. Bacteriologic studies. J Lab Clin Med 1971;77:821-828
2. Moellering RC Jr, Weinberg AN. Studies on antibiotic synergism against enterococci. II. Effect of various antibiotics on the uptake of 14C-labeled streptomycin by enterococci. J Clin Invest 1971;50:2580-2584
3. Davis BD. Mechanism of bactericidal action of aminoglycosides. Microbiol Rev 1987;51:341-350
4. Davis BD, Chen L, Tai PC. Misread protein creates membrane channels: an essential step in the bactericidal action of aminoglycosides. Proc Natl Acad Sci U S A 1986;83:6164-6168
5. Berk DP, Chalmers T. Deafness complicating antibiotic therapy of hepatic encephalopathy. Ann Intern Med 1970;73:393-396
6. Riff U, Jackson GG. Pharmacology of gentamicin in man. J Infect Dis 1971;124(Suppl):S98-S105
7. Siber GR, Echeverria P, Smith AL, Paisley JW, Smith DH. Pharmaco kinetics of gentamicin in children and adults. J Infect Dis 1975; 132:637-651
8. Dager WE. Aminoglycoside pharmacokinetics: volume of distribution in specific adult patient subgroups. Ann Pharmacother 1994:28:944-951
9. Gordon RC, Regamey C, Kirby WMM. Serum protein binding of the aminoglycoside antibiotics. Antimicrob Agents Chemother 1972; 2:214-216
10. Walker JM, Wise R. The pharmacokinetics of amikacin and gentamicin in volunteers: a comparison of individual differences. J Antimicrob Chemother 1979;5:95-99
11. Dickson CJ, Schwartzman MS, Bertino JS Jr. Factors affecting aminoglycoside disposition: effects of circadian rhythm and dietary protein intake on gentamicin pharmacokinetics. Clin Pharmacol Ther 1986:39:325-328
12. Lockwood WR, Bower JD. Tobramycin and gentamicin concentrations in the serum of normal and anephric patients. Antimicrob Agents Chemother 1973:3:125-129
13. McHenry MC, Wagner JG, Hall PM, Vidt DG, Gavan TL. Pharmacoki netics of amikacin in patients with impaired renal function. J Infect Dis 1976;134(Suppl):S343-S348
14. Regeur L, Colding H, Jensen H, Kampmann JP. Pharmacokinetics of amikacin during hemodialysis and peritoneal dialysis. Antimicrob Agents Chemother 1977;11:214-218
15. Agarwal R, Toto RD. Gentamicin clearance during hemodialysis: a comparison of high-efficiency cuprammonium rayon and conventional cellulose ester hemodialyzers. Am J Kidney Dis 1993;22:296-299
16. Kuhar MJ, Mak LL, Lietman PS. Autoradiographic localization of [3H]gentamicin in the proximal renal tubules of mice. Antimicrob Agents Chemother 1979;15:131-133
17. Goitein K, Michel J, Sacks T. Penetration of parenterally administered gentamicin into the cerebrospinal fluid in experimental meningitis. Chemotherapy 1975;21:181-188
18. Briedis DJ, Robson HG. Cerebrospinal fluid penetration of amikacin. Antimicrob Agents Chemother 1978;13:1042-1043
19. Brown RB, Kruse JA, Counts GW, Russell JA, Christou NV, Sands ML (Endotracheal Tobramycin Study Group). Double-blind study of endotracheal tobramycin in the treatment of gram-negative bacterial pneumonia. Antimicrob Agents Chemother 1990;34:269-272
20. Ramsey BW, Dorkin HL, Eisenberg JD, Gibson RL, Harwood IR, Kravitz RM, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993:328:1740-1746
21. Steinkamp G, Tümmler B, Gappa M, Albus A, Potel J, Doring G, et al. Long-term tobramycin aerosol therapy in cystic fibrosis. Pediatr Pu/mono/ 1989;6:91-98
22. MacLusky IB, Gold R, Corey M, Levison H. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Pulmonol 1989;7:42-48
23. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, WilliamsWarren J, et al (Cystic Fibrosis Inhaled Tobramycin Study Group). Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. NEnglJMed 1999:340:23-30
24. Rubenstein E, Goldfarb J, Keren G, Blumenthal M, Treister G. The penetration of gentamicin into the vitreous humor in man. Invest Ophthalmol Vis Sci 1983:24:637-639
25. Alfthan 0, Renkonen OV, Sivonen A. Concentration of gentamicin in serum, urine and urogenital tissue in man. Acta Pathol Microbiol Scand [B] Suppl 1973;241:92-94
26. Pitt HA, Roberts RB, Johnson WD Jr. Gentamicin levels in the human biliary tract. J Infect Dis 1973:127:299-302
27. Vaudaux P, Waldvogel FA. Gentamicin inactivation in purulent exudates: role of cell lysis. J Infect Dis 1980;142:586-593
28. Luft FC, Bloch R, Sloan RS, Yum MN, Costello R, Maxwell DR. Comparative nephrotoxicity of aminoglycoside antibiotics in rats. J Infect Dis 1978;138:541-545
29. Kahlmeter G, Kamme C. Prolonged excretion of gentamicin in a patient with unimpaired renal function [letter]. Lancet 1975;1:286
30. Ho JL, Barza M. Role of aminoglycoside antibiotics in the treatment of intra-abdominal infection. Antimicrob Agents Chemother 1987;31: 485-491
31. Gorbach SL. Treatment of intra-abdominal infections. J Antimicrob Chemother 1993;31(Suppl A):67-78
32. Leibovici L, Paul M, Poznanski O, Drucker M, Samra Z, Konigsberger H, et al. Monotherapy versus -lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study [published erratum appears in Antimicrob Agents Chemother 1997:41:2595]. Antimicrob Agents Chemother 1997:41:1127-1133
33. Hughes WT, Armstrong D, Bodey GP, Brown AE, Edwards JE, Feld R, et al (Infectious Diseases Society of America). 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 1997:25:551-573
34. EORTC International Antimicrobial Therapy Cooperative Group. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. NEnglJMed 1987:317:1692-1698
35. Enderlin G, Morales L, Jacobs RF, Cross JT. Streptomycin and alternative agents for the treatment of tularemia: review of the literature. Clin Infect Dis 1994;19:42-47
36. DiNubile MJ. Short-course antibiotic therapy for right-sided endocarditis caused by Staphylococcus aureus in injection drug users. Ann Intern Med 1994:121:873-876
37. Solera J, Espinosa A, Martinez-Alfaro E, Sanchez L, Geijo P, Navarro E, et al. Treatment of human brucellosis with doxycycline and gentamicin. Antimicrob Agents Chemother 1997;41:80-84
38. Francioli P, Ruch W, Stamboulian D. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone and netilmicin for 14 days: a prospective multicenter study. Clin Infect Dis 1995;21:1406-1410
39. Betts RF, Valenti WM, Chapman SW, Chonmaitree T, Mowrer G, Pincus P, et al. Five-year surveillance of aminoglycoside usage in a university hospital. Ann Intern Med 1984;100:219-222
40. Lee JT Jr. Three-year experience with amikacin sulfate as an exclusive surgical aminoglycoside in a large acute-care hospital. Am J Med 1985;79(Suppl lA):37-42
41. Gerding DN, Larson TA. Resistance surveillance programs and the incidence of gram-negative bacillary resistance to amikacin from 1967 to 1985. Am J Med 1986;80(Suppl 6B):22-28
42. Peetermans WE, Bobbaers HJ. Amikacin as first-choice aminoglycoside in a medical intensive care unit: a one-year bacteriological surveillance study. J Chemother 1996;8:17-24
43. Meier B, Metzger U, Müller F, Siegenthaler W, Lüthy R. Successful treatment of a pancreatic Nocardia astéroïdes abscess with amikacin and surgical drainage. Antimicrob Agents Chemother 1986:29:150-151
44. Gombert ME, Aulicino TM. Synergism of imipenem and amikacin in combination with other antibiotics against Nocardia astéroïdes. Antimicrob Agents Chemother 1983;24:810-811
45. Wallace RJ Jr, Steele LC, Sumter G, Smith JM. Antimicrobial susceptibility patterns of Nocardia asteroides. Antimicrob Agents Chemother 1988:32:1776-1779
46. Chiu J, Nussbaum J, Bozzette S, Tilles JG, Young IS, Leedom J, et al (California Collaborative Treatment Group). Treatment of disseminated Mycobacterium avium complex infection in AIDS with amikacin, ethambutol, rifampin, and ciprofloxacin. Ann Intern Med 1990: 113:358-361
47. Wallace RJ Jr, Swenson JM, Silcox VA, Bullen MG. Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities. J Infect Dis 1985:152:500-514
48. Sexton DJ, Tenenbaum MJ, Wilson WR, Steckelberg JM, Tice AO, Gilbert D, et al (Endocarditis Treatment Consortium Group). Ceftriaxone once daily for four weeks compared with ceftriaxone plus gentamicin once daily for two weeks for treatment of endocarditis due to penicillin-susceptible streptococci. Clin Infect Dis 1998:27:1470-1474.
49. Bernstein JM, Gorse GJ, Linzmayer I, Pegram PS, Levin RD, Brummett RE, et al. Relative efficacy and toxicity of netilmicin and tobramycin in oncology patients. Arch Intern Med 1986:146:2329-2334
50. Traynor AM, Nafziger AN, Bertino JS Jr. Aminoglycoside dosing weight correction factors for patients of various body sizes. Antimicrob Agents Chemother 1995;39:545-548
51. Spyker DA, Guerrant RL. Dosage nomograms for aminoglycoside antibiotics. Hosp Formulary 1981:16:132
52. Cockcroft DW, Gault MH. Prediction of creatine clearance from serum creatinine. Nephron 1976;16:31-41
53. O'Connell MB, Dwinell AM, Bannick-Mohrland SD. Predictive performance of equations to estimate creatinine clearance in hospitalized elderly patients. Ann Pharmacother 1992:26:627-635
54. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987;155:93-99
55. Moore RD, Smith CR, Lietman PS. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med 1984;77:657-662
56. Moore RD, Smith CR, Lietman PS. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis 1984;149:443-448
57. Anderson ET, Young LS, Hewitt WL. Simultaneous antibiotic levels in "breakthrough" gram-negative rod bacteremia. Am J Med 1976; 61:493-497
58. McCormack JP, Jewesson PJ. A critical réévaluation of the "therapeutic range" of aminoglycosides. Clin Infect Dis 1992:14:320-339
59. Massey KL, Hendeles L, Neims A. Identification of children for whom routine monitoring of aminoglycoside serum concentrations is not cost effective. J Pediatr 1986;109:897-901
60. Bennett WM, Plamp CE, Gilbert DN, Parker RA, Porter GA. The influence of dosage regimen on experimental gentamicin nephrotoxicity: dissociation of peak serum levels from renal failure. J Infect Dis 1979:140:576-580
61. Preston SL, Briceland LL. Single daily dosing of aminoglycosides. Pharmacotherapy 1995:15:297-316
62. Dew RB III, Susla GM. Once-daily aminoglycoside treatment. Infect Dis Clin Pract 1996:5:12-24
63. Bailey TC, Little JR, Littenberg B, Reichley RM, Dunagan WC. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997;24:786-795
64. Ali MZ, Goetz MB. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997;24:796-809
65. Hatala R, Dinh TT, Cook DJ. Single daily dosing of aminoglycosides in immunocompromised adults: a systematic review. Clin Infect Dis 1997;24:810-815
66. Fantin B, Carbon C. Importance of the aminoglycoside dosing regimen in the penicillin-netilmicin combination for treatment of Enterococcus faeca//s-induced experimental endocarditis. Antimicrob Agents Chemother 1990;34:2387-2391
67. Nicolau D, Quintlliani R, Nightingale CH. Once-daily aminoglycosides [published erratum appears in Conn Med 1992;56:694]. Conn Med 1992;56:561-563
68. Gilbert DN. Aminoglycosides. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. Voll. 4th ed. New York: Churchill Livingstone; 1995. pp 279-306
69. Bryan LE. General mechanisms of resistance to antibiotics. J Antimicrob Chemother 1988;22(Suppl A):l-15
70. Davies JE. Resistance to aminoglycosides: mechanisms and frequency. Rev Infect Dis 1983;5(Suppl 2):S261-S266
71. Phillips I, King A, Shannon K. Prevalence and mechanisms of aminoglycoside resistance: a ten-year study. Am J Med 1986;80(Suppl 6B):48-55
72. Saavedra S, Vera D, Ramîrez-Ronda CH. Susceptibility of aerobic gram-negative bacilli to aminoglycosides: effects of 45 months of amikacin as first-line aminoglycoside therapy. Am J Med 1986; 80(Suppl 6B):65-70
73. Ruiz-Palacios GM, Ponce de Leon S, Sifuentes J, Ponce de Leon S, Calva JJ, Huazano F, et al. Control of emergence of multi-resistant gram-negative bacilli by exclusive use of amikacin. Am J Med 1986;80(Suppl 6B):71-75
74. Calderwood SA, Wennersten C, Moellering RC It, Kunz U, Krogstad DJ. Resistance to six aminoglycosidic aminocyclitol antibiotics among enterococci: prevalence, evolution, and relationship to synergism with penicillin. Antimicrob Agents Chemother 1977;12:401-405
75. Gordon S, Swenson J, Facklam R, Pigott N, Hill B, Cooksey R (NNIS Enterococcal Study Group). A multicenter study of the epidemiology of enterococcal infections [abstract]. Program Abstr Intersci Conf Antimicrob Agents Chemother 1989;29:233
76. Spiegel CA, Huycke M. Endocarditis due to streptomycin-susceptible Enterococcus faecalis with high-level gentamicin resistance. Arch Intern Med 1989;149:1873-1875
77. Zervos MJ, Kauffman CA, Therasse PM, Bergman AG, Mikesell TS, Schaberg DR. Nosocomial infection by gentamicin-resistant Streptococcus faecalis. Ann Intern Med 1987;106:687-691
78. Morrison AJ Jr, Wenzel RP. Nosocomial urinary tract infections due to Enterococcus: ten years' experience at a university hospital. Arch Intern Med 1986;146:1549-1551
79. Barclay ML, Begg EJ. Aminoglycoside toxicity and relation to dose regimen. Adverse Drug React Toxicol Rev 1994:13:207-234
80. Smith CR, Lipsky 11, Laskin ÖL, Hellmann DB, Mellits ED, Longstreth J, et al. Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N EnglJ Med 1980:302:1106-1109
81. Kahlmeter G, Dahlager Jl. Aminoglycoside toxicity-a review of clinical studies published between 1975 and 1982. J Antimicrob Chemother 1984;13(Suppl A):9-22
82. Kumin GD. Clinical nephrotoxicity of tobramycin and gentamicin: a prospective study. JAMA 1980:244:1808-1810
83. Tulkens PM. Experimental studies on nephrotoxicity of aminoglycosides at low doses: mechanisms and perspectives. Am J Med 1986;80(Suppl 6B):105-114
84. Eisenberg JM, Koffer H, Glick HA, Connell ML, Loss LE, Talbot GH, et al. What is the cost of nephrotoxicity associated with aminoglycosides? Ann Intern Med 1987:107:900-909
85. Bertino JS Jr, Booker LA, Franck PA, Jenkins PL, Franck KR, Nafziger AN. Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis 1993:167:173-179
86. Cimino MA, Rotstein C, Slaughter RL, Emrich LJ. Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin treatment. Am J Med 1987:83:1091-1097
87. Goetz MB, Sayers J. Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination [published erratum appears in J Antimicrob Chemother 1993:32:925]. J Antimicrob Chemother 1993;32:325-334
88. Leehey DJ, Braun Bl, Tholl DA, Chung LS, Gross CA, Roback JA, et al. Can pharmacokinetic dosing decrease nephrotoxicity associated with aminoglycoside therapy? J Am Soc Nephrol 1993:4:81-90
89. Gatell JM, Ferran F, Araujo V, Bonet M, Soriano E, Traserra J, et al. Univariate and multivariate analyses of risk factors predisposing to auditory toxicity in patients receiving aminoglycosides. Antimicrob Agents Chemother 1987;31:1383-1387
90. Bevan DR, Donati F. Muscle relaxants. In: Barash PG, Cullen BF, Stoelting RK, editors. Clinical Anesthesia. 3rd ed. Philadelphia: Lippincott-Raven; 1997. p 398
91. Gilbert DN, Wood CA, Kohlhepp SJ, Kohnen PW, Houghton DC, Finkbeiner HC, et al. Polyaspartic acid prevents experimental aminoglycoside nephrotoxicity. J Infect Dis 1989:159:945-953
92. Hitt CM, Klepser ME, Nightingale CH, Quintiliani R, Nicolau DP. Pharmacoeconomic impact of once-daily aminoglycoside administration. Pharmacotherapy 1997:17:810-814